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INTRODUCTION 
 
Cancer is becoming a leading cause of death in many countries of the 
world.  Thyroid malignancy is relatively rare, but represents the most frequent 
form of cancer of the endocrine glands.  It may present as solitary   nodule or as 
a dominant nodule in multinodular goitre.   Therefore both conditions should 
be carefully evaluated to detect any underlying  malignant foci.    In India 
thyroid cancer responsible for 1.2% cases of all malignant tumors.  Exposure to 
ionizing radiation, changing levels of iodine nutrition and improvement in the 
various investigations to identify malignant foci have all proposed as 
explanations for world wide increase in the incidence of thyroid malignancy.  
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AIM OF STUDY 
 
 To determine the frequency of thyroid malignancy in solitary nodular 
goitre and multinodular goitre patients who are undergoing thyroidectomy  in 
our institution.  
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MATERIALS AND METHODS 
 
 This retrospective study was carried out in our hospital  over the period 
of two years from 2008 to 2009.   All patients who are underwent different 
types of thyroid surgery during this period were included in this study.    All 
data including age gender, relevant history, investigations like untrasonography  
and fine needle aspiration cytology, duration of hospital stay, and final 
histopathology report were recorded on a standard form.  
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REVIEW OF LITERATURE 
HISTORICAL REVIEW :  
Year Event 
2700 BC Emperor Shen Nung’s prescriptions (first published in Pen  Tsao, 
the herbal of the Chinese  pharmacopoeia, 1596) mention the use 
of seaweed for the treatment of goitre.  
300 BC Ayur Veda, Hindu holy text, discusses goitre. 
340 Ko-Hung, Chinese alchemist, recommends seaweed for treatment 
of goitre among people living in mountains.  
961 Abdul Kasim, a personal physician to Caliph El-Hakin III of 
Codoba, is first to describe thyroidectomy for goitre and perform a 
needle biopsy of the thyroid. 
1170 Roger of Salerno uses seaweed in the treatment of goitre.  
1475 Chinese physician, Wang Hei, recommended treatment of goitre 
with minced thyroid. 
1500 Leonardo da Vinci is the first person to recognize and draw the 
thyroid gland. 
1543 Andreas Vesalius provides first anatomic description and 
illustration of the thyroid gland. 
1563 Eustachius introduces the term “isthmus”.  
1646 First Known Thyroidectomy was described by Wilhelm Fabricius 
of Jeneva. 
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1656 Thomas Wharton names gland ‘Thyroid’ after the shape of an 
ancient Greecian shield. 
1669 Albrecht van Haller describes constipation as a complication of 
cretinism. 
1789 P.S. Dessault has done well documented partial  thyroidectomy. 
1808 Guilliance dupuytren performed a total thyroidectomy for tumor. 
1811 Bernard Courtois discovers iodine by oxidizing burnt seaweed  
with sulfuric acid.  
1818 Goitre reported in British Columbia. 
1820 Jean Francois Coindet concludes that iodine deficiency causes 
goitre and begins treatment of goitre with iodine.  
1825 C. Parry describes exophthalmic goitre. 
1834 Robert Graves describes a syndrome of palpitations, goitre, and 
exophthalmos in three women.  
1848 C. Von Basedown describes exophthalmic goitre. 
1849 J.L. Prevost adds iodine to food and water to prevent goitre.  
1862 A.Trousseau introduces the term “Graves disease”  
1867 A.von Graefe describes lid lag in thyrotoxicosis (Basedow’s 
disease) 
1873 Th. Billroth describes tetany following total thyroidectomy 
1883 E.T. Kocher calls attention to myxedema following 
thyroidectomy. 
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1886 Pierre Marie describes the characteristic tremor of 
hyperthyroidism. 
1891 G.R. Murray introduces the use the thyroid extract to treat 
myxedema.  
1896 B. Riedel publishes first description of chronic, fibrous thyroiditis.  
1897 Pendred describes associations of goiter with deaf – mutism. 
1902 F. de Quervain describes subacute granulomatous thyroiditis. 
1907 David Marine publishes that iodine is necessary for thyroid 
function. 
1912 Kocher coins term Jod Basedow for iodine overdosage.  
1915 E.A. Kendall isolates thyroxine.  
1917 Thyroxine introduced into commercial distribution in the Unite 
States  for $350 per gram.  
1926 First goitre belt identified in USA.  
1927 Harington determines the chemical structure of thyroxine. 
1936 Dr. Saul Hertz first proposes the use of radioactive iodine for the 
study of the thyroid.  
1943 Kennedy observes that thiourea is goitrogenic.  
1948 T. Tempka, J. Publish the use of fine needle thyroid biopsy as a 
diagnostic method.  
1951 B. Duffy identify cancer in children following radiation. 
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1952 Lawson, Rimington, and Searele synthesize carbimazole.  
1956 Roitt and Doniach demonstrate autoantibodies in Hashimoto’s 
disease.  
1965 E.D. Williams reports 17 cases of cancer of the thyroid and 
phaeochromocytoma. 
1966 J.H. Sipple describe the first case of multiple endocrine neoplasia 
type2. 
1970 L.Braverma, S. Ingbar, and K. Sterling discover T4 to T3 
conversion. 
1974 S. Refetoff and L. DeGroot identify thyroid hormone resistance.  
1998 Recombinant human TSH approved for clinical use in the United 
States. 
2002 Thomas Scanlan discovers 3 –iodo – thyronine (T1 amine)  
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REVIEW OF THYROID MALIGNANCY 
ANATOMY OF THYROID 
 Thyroid is a brownish red and highly vascular gland located anteriorly in 
the lower neck.   It extents from fifth cervical to first thoracic vertebrae. It  has 
two lobes connected by isthmus.  
 Weight of the gland is 25 to 30 gram, Height of the gland is 50 – 60 
mm.  A conical pyramidal lobe often ascends from isthmus  towards hyoid 
bone. 
 It is invested by the middle layer of the deep cervical fascia.   It has 
inner thin true capsule which adheres closely to the gland.  Extension of the 
capsule to the gland forms numerous septae that divides the gland into lobes 
and lobules.   
FASCIA AND LIGAMENT 
Thyroid ensheathed by visceral fascia a division of middle layer of  deep 
cervical fascia, which attaches it firmly to laryngo-skeleton.  
Anterior suspensory ligament extends from supero-medial aspect of 
each lobe to cricoid and thyroid cartilage.  Posterior suspensory ligament 
(Berry’s ligament) attaches postero medial aspect of thyroid to cricoid 
cartilage, I, II tracheal rings, responsible for movement during deglutition. 
RELATION TO STRAP MUSCLES  
The lateral surface of thyroid is covered by sternothyroid muscle.   Its 
attachment to the oblique line of thyroid cartilage prevents the superior pole 
extending superiorly under thyrohyoid muscle.  
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More anteriorly sternohyoid and superior belly of omohyoid covers the 
gland. 
VASCULAR SUPPLY  
 The arterial supply to the gland comes from superior and inferior thyroid 
arteries and occasionally thyroidea ima artery.   These vessels have abundant 
collateral anastomoses with each other, both ipsilaterally and contralaterally.   
 Superior thyroid artery is the first  branch of the extemal carotid artery.  
In rare cases, it may arise from the common carotid artery just before its 
bifurcation.   The superior thyroid artery descends laterally to the larynx under 
cover of the omohyoid and stemohyoid muscles. This artery runs superficially 
on the anterior border of the lateral lobe, sending a branch deep into the gland 
before curving towards the isthmus were it anastomoses with the contralateral  
artery. 
 Cephalad to the superior pole, the extemal branch of the superior 
laryngeal nerve runs with the superior thyroid artery before turning medially to 
supply the cricothyroid muscle.  High ligation of the superior thyroid artery 
during thyroidectomy places this nerve at risk of inadvertent injury, which 
would produce dysphonia by altering pitch regulation.    
INFERIOR THYROID ARTERY AND RECURRENT LARYNGEAL 
NERVE 
 The inferior thyroid artery arises from the thyrocervical trunk, a branch 
of the subclavian artery.  It ascends vertically and then curves medically to 
enter the tracheoesophageal groove in a plane posterior to the carotid sheath.  
Most of its branches penetrate the posterior aspect of the lateral lobe.  
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 The inferior thyroid has a variable branching pattern and is closely 
associated with the recurrent laryngeal nerve.  The latter also ascends in the 
tracheoesophageal groove and enters the larynx between the inferior cornu of 
the thyroid cartilage  and the arch of the cricoids.  The recurrent laryngeal 
nerve can be found after it emerges from the superior thoracic outlet, in a 
triangle bounded laterally by the common carotid artery, medially by the 
trachea and superiorly by the thyroid lobe.  
 The relationship between the nerve and the inferior thyroid artery is 
highly variable, as demonstrated by the classic work of Reed, who was  
described 28 variations in this relationship at 1943.  The nerve can be found  
deep to the inferior thyroid artery (40%)  superficially (20%) or between 
branches of the artery (35%).  Significantly, the relationship between nerve and 
artery on one side of the neck is similar to that found on the other side in only 
17% of the population.  Furthermore, at the level of the inferior thyroid artery, 
branches of the recurrent laryngeal nerve that are extralaryngeal may be present 
(5%).  Preservation of all  those branches is important during thyroidectomy.  
 Another hint to the location of the recurrent  larynegeal nerve is the 
Zuckerkandl tubercle, an extension of the thyroid, close to the Berry ligament.  
LOCATION OF PARATHYROID 
 Superior parathyroid located in posterior surface of upper pole. 
 Inferior parathyroid located in lateral surface of lower pole.  
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VENOUS DRAINAGE  
3 pairs of veins present.  
Superior Thyroid vein drains into internal jugular vein. 
Middle thyroid vein which is directly drains into internal jugular vein. 
Inferior thyroid vein drains into right and left brachiocephalic vein. 
LYMPHATIC DRAINAGE 
Into prelaryngeal (Delphian), pretracheal, paratracheal lymph nodes, 
cervical lymph nodes then finally into mediastainal nodes. 
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Location of Parathyroid 
 
 
Location of thyroid 
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Vascular and venous drainage 
 
 
Anatomy of the recurrent laryngeal nerve 
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SOLITARY NODULE OF THYROID 
 It is defined as palpably discrete swelling within an apparently normal 
gland. 
 May be benign or malignant. 
 Benign classified into cysts (or) adenoma either toxic or non toxic 
EPIDEMIOLOGY 
 Prevalence varies from each region depending on iodine sufficiency. 
5% in sufficient areas. Upto 50% in insufficient areas. 
 More common in women. 
TYPES OF THYROID NODULES 
Adenoma 
 
Macrofollicular 
adenoma 
Microfollicular 
adenoma (fetal) 
Embryonal adenoma 
Hurthle cell adenoma 
Atypical adenoma 
Adenoma with 
papillae 
Signet-ring adenoma 
Carcinoma 
 
Papillary 
 
Follicular 
Medullary 
Anaplastic 
Thyroid lymphoma 
Cyst 
 Simple cyst 
 Cystic/solid 
tumors 
Colloid nodule 
 
Dominant nodule in a 
multinodular goiter 
Others 
Inflammatory thyroid 
disorders 
 Subacute thyroiditis 
 Chronic lymphocytic 
thyroiditis 
 Granulomatous disease 
Developmental abnormalities 
Dermoid 
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SYMPTOMS 
 Non toxic are asymptomatic 
 Toxic ones are gives symptoms depends upon toxicity 
 Neck mass if it is a large one. 
DIFFERENTIAL DIAGNOSIS 
- Cyst 
- Non functioning adenoma 
- Primary Thyroid Cancer 
- Lymphoma 
- Metastatic Cancer 
THYROID MALIGNANCIES 
 The normal thyroid composed of two main parenchymal cell types.   
Follicular cells line the colloid follicles which gives rise to well differentiated 
cancers.  The second cell type is “C” cells or parafollicular cells gives rise to 
medullary thyroid cancer.    Immune and stromal cells gives rise to lymphoma 
and sarcoma respectively. 
 90% are well differentiated cancers, 5-9 % are medullary thyroid cancer, 
and 1-2% are anaplastic, 1-3% are lymphoma, 1% sarcoma.  
 Among well differentiated cancer papillary type is 80 to 85 %,                        
10-15% are follicular, 3 to 5%  Hurthle cell type.  Thyroid malignancies are 
categorized by level of clinical aggressiveness. Well differentiated are papillary 
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and follicular cancer.   Intermediate are hurthle cell and insular cell cancers.  
Poorly differentiated is anaplastic cancer. 
RISK  FACTORS 
 Extremes of age.  
 Female gender  
 Family history of goitre. 
 Family history of thyroid malignancies 
 Past history of radiation. 
 Patients with Hashimoto’s thyroiditis have a 70-fold increased 
risk of developinglymphoma.  
GENETIC FACTORS 
 Most well differentiated tumors  are sporadic.  
 Studies have demonstrated that genetic rearrangement of the RET 
Proto-oncogene in 50% of tumors.  
 Kindreds of papillary cancer with no associated extrathyroid 
tumors.  
 Patients with cowden syndrome.  
 Patients with adenomatous polyposis coli.  
 Family members  of MEN syndrome.  
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WHO CLASSIFICATION OF THYROID MALIGNANCIES 
 
Primary malignancies of follicular cells. 
  Papillary carcinoma 
  Follicular carcinoma  
  Anaplastic carcinoma 
Malignancies of ‘C’ Cells: 
  Medullary carcinoma of thyroid 
Malignancies of mixed follicular and ‘C’ Cells. 
Miscellaneous malignancies  of epithelial cells  
Squamous cell carcinoma  
Adeno carcinoma 
Adeno squamous variety  
Malignancies asso. With FAP 
Muco epidermoid carcinoma. 
Teratoma 
Malignancies of non epithelial cells. 
   Lymphoma 
  Sarcoma 
Secondary Metastasis  of thyroid  
  Malignant melanoma  
  Renal cell carcinoma 
            Bronchogenic carcinoma 
                      Breast carcinoma  
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PAPILLARY CANCER 
 50% of tumors are < 2 cm at presentation.   
 30- 50% are multicentric. 
 < 1 cm are considered as micro papillary lesions. 
 Classical, follicular variant, tall cell, oxyphil, diffuse sclerosing, De-
differentiated are the various types.  
 ‘Psammoma bodies’ and ‘orphan Annie’ nuclei are classical histologic 
features.  
 Microscopic features of papillary cancer include the demonstration of 
true papillae, which occasionally occur in combination with follicles.  
   A combination of the encapsulated variant and the follicular variant 
called lindsay’s tumor. 
 80% cervical nodes has microscopic deposits. 
 Early spread to cervical lymph nodes. 
 Lateral aberrant thyroid is almost a metastatic papillary carcinoma. 
 Most of the tumors are TSH dependent. 
 TSH suppression therapy with thyroxine is appropriate for post 
operatively. 
 Thyroxine reduces the recurrence and improves survival. 
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FOLLICULAR CARCINOMA 
 This is a malignant epithelial tumor with evidence of follicular cell 
differentiation without the features of papillary cancer.  
 Cannot differentiate adenoma from carcinoma by FNAC. 
 Solitary, encapsulated. 
 There are two types, based on the degree of invasiveness of the lesion.  
 Minimally  invasive  type  is a solid, encapsulated, fleshy tumor that 
looks  very much like a simple thyroid adenoma.  
 Widely invasive type shows widespread infiltration of blood vessels, the 
capsule and adjacent  thyroid tissue.  
 Follicular cancer dose not invade lymphatics.  
 Metestasis by blood stream to lungs and bones. 
 Immunostaining  for thyroglobulin is usually positive in this tumor. 
MEDULLARY THYROID CARCINOMA. 
 Accounts for 5-10% of all thyroid cancers.  
 Arises from para follicular C  cells. 
 80% are sporadic, 20%are familial.  Familial cancers can occur as a non-
MEN  form (FMTC) or as a part of MEN either IIA or IIB.  
 Autosomal dominant inheritance.  Mutations of the RET proto-oncogene 
to exclude familial disease.  
 Secretes calcitonin.  It is a tumor  marker and also used for follow up. 
 Familial ones are multifocal, present at younger age, aggressive, 
recurrence is common. 
 Metastasis by blood, and lymphatic. 
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 Sporadic are solitary, older age, good prognosis. 
 Three familial forms of MTC are known. 1) Familial medullary thyroid 
cancer – indolent course with no feature of MEN and a very good 
prognosis. 2) MEN IIA- MTC associated with phaeochromocytomas, 
parathyroid hyperplasia, cutaneous lichen amyloidosis. 3) MEN IIB – 
MTC associated with  marfanoid, with high arched palates, have 
characteristic neuromas on their tongue and eyelids. 
 Total thyroidectomy should be performed in MEN IIB family members 
and the age of 5.  
ANAPLASTIC CARCINOMA 
 Highly aggressive, poorly differentiated and lethal disease.  
 Affects older age. 
 Fifty percentage of cases have concurrent or previous differentiated 
thyroid cancers, but anaplastic cancer can arise de novo.  
 It presents as a rapidly growing mass strangulating the structures of the 
neck.   
 Local and distant metastasis are present at the time of presentation. 
 Anaplastic cancers  are usually spindle or giant cell tumors.   
 The possibility of a secondary deposit in the thyroid  must always be 
considered.  
 Very poor prognosis. 
THYROID LYMPHOMA  
 It represents 5% of all thyroid malignancies.   The incidence is rising 
due to the increase in rates of Hashimoto’s thyroiditis.  
 It is often associated with a history of thyroxine replacement.  
 22 
 Most lymphomas are of diffuse histiocytic type and vary from 
intermediate-to high – grade.   
 Staging is mandatory and total – body scanning is performed.  
 On ultrasound, the thyroid is usually hypoechoic and CT or  MRI cannot 
separate simple Hashimoto’s from lymphoma.  
 FNAC can usually secure a tissue diagnosis.  
 There is no role for thyroidectomy or iodine treatment for thyroid 
Lymphoma.  
 Primary treatment is external-beam  radiation with chemotherapy.  
 5 years survival rates of 80%.  
SYMPTOMS OF THYROID MALIGNANCY 
May not cause symptoms in early stages. 
A lump in the neck. 
Hoarseness of voice 
Difficulty in swallowing. 
Difficulty in breathing. 
Lymph nodes in neck. 
Symptoms of metastasis like bone pain,and headache. 
Primary Tumor (T)a,b 
TX Primary tumor cannot be assessed 
TO No evidence of primary tumor 
T1 Tumor  cm in greatest dimension limited to the thyroid 
T1a Tumor  1 cm, limited to the thyroid 
T1b Tumor > cm but  4 cm in greatest dimension, limited to the thyroid 
T3 Tumor >4cm in greatest dimension limited to the thyroid or any tumor 
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with minimal extra thyroid extension (e.g. extension to sterno thyroid 
muscle or perithyroid soft tissues) 
T4a Moderately advanced disease 
 Tumor of any size extending beyond the thyroid capsule to invade 
subcutaneous soft tissues, larynx, trachea, esophagus or recurrent 
laryngeal nerve. 
T4b Very advanced disease 
 Tumor invades prevertebral facia or encases carotid artery or 
mediastinal vessels. 
oT4a Intrathyroidal anaplastic carcinoma. 
oT4b Anaplastic carcinoma with gross extra thyroid extension. 
 
Regional Lymph Nodes (N)a,b 
 
TX Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
N1 Regional lymph node metastasis 
N1a Metastases to Level VI (pretracheal, paratracheal and prelaryngeal/ 
Delphian lymph nodes) 
N1b Metastases to unilateral, bilateral, or contra lateral cervical (Levels 
I,II,III,IV or retropharyngeal or superior mediastinal lymph nodes 
(Level VII) 
 
Distant Metastasis (M)a 
 
NO No distant metastasis 
M1 Distant metastasis 
STAGING 
Stage – I Papillary carcinoma  
  Below 2cm, Localized to thyroid, 50% are multifocal. 
  Mostly associated with follicular elements. 
  10 Years survival rate is good.   
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Stage – II Papillary Carcinoma  
2-4cm in size, distant spread if <45 years, Limits with in thyroid 
if >45 years. 
Stage – III papillary Carcinoma  
  >4cm in size, extra thyroid extension present.   
  Lymphnode metastasis present  
  Prognosis poor if cervical lymphnodes present. 
Stage – IV Papillary Carcinoma  
Any size with distant metastasis. 
Prognosis poor. 
Stage – I Follicular Carcinoma  
  < 2cm, must be distinguished from follicular adenoma. 
  Prognosis good when vascular invasion absent.  
Stage – II Follicular Carcinoma  
2-4cm, distant spread if < 45 years or limit to thyroid   
> 45 years, prognosis less favourable than papillary carcinoma.  
Stage – III Follicular Carcinoma  
Above >4cm, limits to the thyroid, prognosis poor if cervical 
lymphnodes present.  
Stage – IV Follicular Carcinoma  
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Beyond thyroid capsule with any size.  With distant metastasis 
present.  Prognosis is Poor. 
Stage – I Medullary Thyroid Carcinoma  
  < 2cm in size. 
Stage – II Medullary Thyroid Carcinoma  
  2-4 cm in size with minimal extra thyroid extension.  
Stage – III Medullary Thyroid Carcinoma  
  Any size with lymphnode metastasis. 
Stage – IV Medullary Thyroid Carcinoma  
A. Moderately advanced – absent lymphnodes with absent distant metastasis. 
B. Very advanced - Positive lymphnodes with absent metastasis.   
C. With distant metastasis 
 Staging for Anaplastic Carcinoma:  
  No general accepted staging system. 
  All patients considered as stage IV. 
  It is sub classified small cell and large cell.  
Staging for Hurthle Cell Carcinoma 
   Equivalent stage as non hurthle cell follicular carcinoma.  
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NORMAL HISTOLOGY OF THYROID 
 
 
PAPILLARY CARCINOMA OF THYROID 
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HURTHLE CELL CARCINOMA 
 
 
FOLLICULAR CARCINOMA
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INVESTIGATIONS 
1. Thyroid  Function Test 
 Usually within normal limits in malignancies. Not a useful predictor for 
malignancies. 
2.  X-Ray Soft tissue neck 
 For tracheal  position , some time shows fine stippled calcification in 
papillary cancer, or signet ring calcification in old cysts. 
3.  FNAC 
Most accurate , using 22 – 25 G needles, specimen adequacy should be 
>2 slides with 6to 8 cell clusters.  > 95%  accuracy, False positive -1%, False 
negative 2%.  Clearly diagnose  90% of papillary carcinoma.  Can’t 
differentiate between Follicular adenoma from carcinoma.  
4.  Laryngoscopy 
 To evaluate the vocal  cord status pre operatively. 
5.  Ultra sound  Neck 
 Identify nodules that are difficult to palpate and <2 cm in size,  useful to 
identify cystic  nodules, useful to perform FNAC under it guidance , 
monitoring the size of the nodule, evaluate the lymphnode status of neck.  It 
can suggest malignancy by sonographic features.  
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6.  Radio active iodine study  
It provides the evidence for diagnose MNG, and rarely malignancy.Cold 
nodule suggestive of  malignancy (10%).chance of malignancy is low when a 
nodule is hyper functioning.Tool for identify distant metastasis. 
7. C T Scan neck 
 Should be done without iodine containing  contrast.  
Identify soft tissue involvement, and lymphnode status. 
 Useful for identify retrosternal extension.  
8.  PET scan  
 Mainly used for identify the metastasis, recurrence and follow up.  
9.       SERUM CALCITONIN ASSAY in medullary carcinoma of thyroid. 
PROGNOSTIC FACTORS FOR IMPROVED SURVIVAL 
Age of the patient ,>40 yrs poor prognosis. 
Type of the cancer. 
The stage of the cancer. 
General health of the patient 
Presence or absence of metastasis. 
Whether he associated with MEN 2B. 
 30 
TREATMENT MODALITIES 
SURGERY 
 May be lobectomy or near total or total thyroidectomy. 
 Lobectomy can be done in < 2 cm size, with well differentiated 
histology, absent lymphnode involvement, solitary, tumors. 
 Total thyroidectomy can be done in high risk patients with low rates 
of  local recurrence.  
 Lymphadenectomy in well differentiated cancer has little or no effect 
on prognosis. Berry picking can be done in this tumors.  
 When central nodes are  present, a clearance should be performed in 
the way of central neck node dissection. 
 When lymphnodes are present in the lateral compartment, a 
functional neck dissection including levels II-V is performed. 
RADIATION THERAPY  
 In the form of radio active iodine. Higher doses than used to 
diagnose are used. Since only thyroid tissue takes up iodine, RAI  
destroys cancer cells. 
 Indications are > 2.5 cm in size, locally invasive, multi focal, 
presence of metastasis. 
 In high risk groups 131 I ablation is considered standard management 
because large residual thyroid beds with high uptake may obscure 
metastasis, serum thyroglobulin is a better marker of recurrence after 
131 I ablation. 
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 It started after four week of total or near total thyroidectomy having 
allowed the TSH to rise to 50iu or more.   At third day post treatment 
scans are obtained if the patients activity false to permitted levels he 
or she is discharged with advice by the medical physicist regarding 
contact with other people. Thyroxine at replacement doses  started. 
 After 4 months the thyroglobulin is measured and a repeat total-body 
scans are performed  after stopped thyroxine for at least 10 days.  If 
successful ablation is achieved  after the first dose of 131 I treatment 
patient discharged with replacement dose of thyroxine and follow up. 
 If initial ablation is into successful, remnant ablation will need to be 
performed at 6-12 monthly intervals until ablation is complete. 
RADIOTHERAPY  
 Post operatively it can be given in a form of either external beam or 
internal with needles, seeds,  and wires. 
CHEMOTHERAPY  
Combined chemotherapy with bleomycin, adriamycin, and platinum 
compounds are tried in advanced cancer 
HORMONE THERAPY 
Is a cancer treatment that removes hormones or blocks their action. 
Since most tumors are TSH dependent, suppressive doses of thyroxine is 
enough to prevent recurrence. 
TARGETED THERAPY 
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            Drugs that specifically identify and attack cancer cells in the treatment 
of thyroid cancer are under study.  Tyrosine kinase receptor inhibitors are 
under trial. 
TREATMENT OPTIONS BY STAGE. 
STAGE 1 AND 2 PAPILLARY OR FOLLICULAR CARCINOMA. 
 Near total or Total thyroidectomy with or without RAI therapy. 
 Hemithyroidectomy  with or without  lymphadenectomy followed by 
Hormone therapy.. 
STAGE 3 PAPILLARY OR FOLLICULAR. 
 Total Thyroidectomy with lymphadenectomy with or without RAI  
therapy. 
STAGE 4 PAPILLARY OR FOLLICULAR. 
 Total thyroidectomy  with lymphadenectomy  plus radiation therapy if 
only lymph node metastasis is present. 
 If distant metastasis is present treatment is usually palliative in the form 
of RAI therapy, external beam RT, Hormone therapy, clinical trial of 
chemo therapy or targeted therapy. 
TREATMENT FOR MEDULLARY THYROID CARCINOMA   
 Total thyroidectomy with central lymphnode dissection. 
 External beam radio therapy as palliative to relieve symptoms.   
 Chemotherapy as palliative treatment for tumors that have distant 
spread.  
TREATMENT FOR ANAPLASTIC CARCINOMA 
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 Tracheostomy, isthumectomy are palliative treatment to relieves 
symptoms.   
 Total thyroidectomy as palliative treatment when tumor not spread away 
from the gland.  
 Combined thyroidectomy, external beam radio therapy, chemotherapy 
are under trial. 
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STEPS OF THYROIDECTOMY 
 Patient under general anaesthesia with semi-fowler’s position. 
 Skin crease incision is made 2cm from the jugular notch. Length of the 
incision depends up on the size of the goitre.  
 Using mayo’s scissors superior and inferior flaps are raised up to thyroid 
notch superiorly and suprasternal notch inferiorly. It is important to stay 
anterior to the jugular veins, under the platysma, to achieve a bloodless 
dissection.  These skin flaps are held apart by one or two joll’s self- 
relatining retractors or wishbone ratractors depending on the surgeon’s 
preference.  
 Deep cervical fascia is opened longitudinally. 
 Strap muscles are separated and retracted laterally. 
 The sternohyoid and sternothyroid muscles are some time divided for 
greater exposure of a large or vascular lobe.  It is recommended to do 
the transection in the upper thirds of these muscles to avoid nerve injury.  
  Freeing of the lobe by using the lateral approach.  Another approaches 
are cranial or superior approach. This later approach is preferable when 
the goitre is large.  Superior approach is useful when the goitre is 
retrosternal. 
 The use of graspers should be avoided even in non vascular glands, if 
malignancy is suspected, to avoid breaching the capsule of the lobe.  
 With the aid of firm lateral traction of the assistant with the surgeon 
applying a gentle medial and upward pull in the dislocated lobe.  
 The operative field between the carotid sheath and the thyroid gland can 
be opened up with careful blunt and sharp dissection.   As soon as  the 
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inferior thyroid artery is identified, it is followed medially to its 
intersection with the recurrent laryngeal nerve, if already visualized in 
the trachea-esophageal groove.  Looping the trunk of the artery at this 
stage facilities the dissection and improves the exposure of the recurrent 
laryngeal nerve.  
 The next step is to fully mobilize the lobe by ligation of the superior 
pole vessels.  Here care should be taken to preserve the external branch 
of the superior laryngeal nerve.  The upper pole is exposed by gentle 
downward traction on the lobe and blunt dissection laterally to break 
down fibrous adhesions. The ESLN is usually identified on the surface 
of the inferior pharyngeal constrictor before it enters the cricothyroid 
muscles.  
 This is achieved by opening the space medial to the superior thyroid 
artery with an artery forceps or a pledget.   Due to anatomical variations 
and frequent intramuscular locations (10%) it is only visualized on the 
constrictor in about 70% of cases.   Mass ligation of the upper pole 
vessels should be avoided as the nerve passes between the branches of 
the vessels.  
 Each pedicles are divided individually close to the gland with 
absorbable suture material. 
 The RLN’s ‘encountered’ usually near the ligament of Berry, rather than 
being dissected along it is entire length.  The critical point is superiority, 
where the nerve enters the ligament of Berry and could be easily injured 
while handling the organ of Zuckerkandl. From here  medial dissection 
between the gland  and the trachea is continued.  It is mandatory to 
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avoid any form of electro – cautery in the vicinity of the RLN as it could 
be damaged by conducted heat.   Troublesome bleeders could be 
controlled with fine absorbable transfixion sutures.  This dissection is 
continued medially until the isthmus is completely freed and the 
transection made close to the opposite lobe.  
 The stump is closed continuously with an absorbable suture in a 
haemostatic manner at the same time avoiding bunching up the tissues.  
 Nerve stimulation during surgery has been shown to help in the 
identification and protection of nerves.  
 Meticulous control of bleeders should be standard practices as the  use 
of drains is not a replacement for hemostasis.   
 If the strap muscles had been transected to improve access to the lobe, 
they should be re-approximated with interrupted absorbable mattress 
sutures like 2-0 chromic catgut.  
 Skin closure can be achieved with subcutaneous stitch after kept a 
corrugated drain.  
 37 
 
 
POSITION OF THE PATIENT 
 
 
BEFORE SKIN INCISION 
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RAISING OF FLAPS 
 
 
OPENING OF DEEP CERVICAL FASCIA 
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MEDIALISATION OF LOBE 
 
 
LIGATION OF SUPERIOR PEDICLE 
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LIGATION OF INFERIOR PEDICLE 
 
SHOWS RECURRENT LARYNGEAL NERVE 
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SHOWS PARATHYROID 
 
SPECIMEN 
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COMPLICATIONS OF THYROIDECTOMY 
 Small hematomas or serous collections under the skin flaps are not 
unusual during the first week.  These resolve spontaneously. 
 Large bleeds requiring reopening and evacuation of heamatoma to 
relieve pressure symptoms.   
 Stridor arising from laryngeal edema due to blockage of venous returns 
by a deep hematoma is best managed by opening the wound urgently.    
 Unilateral recurrent laryngeal nerve occurs in various types like 
complete transection, traction, contusion, burn. Steroids improve the 
neuropraxia. If permanent hoarseness present it was treated by surgery 
like medialization – Type-I thyroplasty, Reinnervation, Primary 
neurorrhaphy. 
 If bilateral recurrent laryngeal nerve injury occurs and both vocal cords 
are fixed in the adducted position, severe airway obstruction, requiring a 
traheostomy. 
 A tracheostomy is usually a last resort. Large doses of hydrocortisone 
are usually give at this stage in an effort to reduce the effect of a 
neuropraxia and the oedema of the injured nerve.  
 Permanent RLN palsy after partial thyroidectomy is reported in the 
literature to be 0-1.3%.  
 Treatment for bilateral recurrent laryngeal nerve are cordotomy, 
arytenoidectomy. 
 Any muscle pains, paresthesia, twitching or cramps before discharge 
indicate hypoparathyroidism and the patients are usually managed 
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accordingly.  10 mls of intravenous calcium gluconate 8 hourly is 
commenced at the same time with oral calcium.  
 If parathyroids injured during surgery, it can be implanted in 
sternomastoid muscle after cutting the gland into 2-3mm pieces with 
clip for identification in future, are in non dominant forearm under 
brachioradialis muscle.   
Thyroid Storm : 
 Is a clinical manifestation of extreme hyperthyroid state, that results in 
significant morbidity and mortality. 
Causes : 
 Commonly encountered during surgery, post-operative states, now-a-
days it occurs in hyperthyroid patients undergoing emergency surgery for other 
causes. Trauma, stress, parturition, after withdrawal of anti thyroid drugs, 
infection. 
Clinical Features : 
High grade fever, confusion, dehydration, vomiting, abdominal pain, 
diarrhoea, delivium, seizure, coma. 
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Treatment : 
1) Fluid correction 
2) Propylthiouracil is the drug of choice. 
3) Proponolol 
4) Esmomol 
5) Steroids 
6) Anti pyretics 
7) Digitalization 
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OBSERVATIONS & CHARTS 
 
Age Group Frequency Percent 
16-25 14 25.9 
26-35 23 42.6 
36-45 13 24.1 
46-55 4 7.4 
Total 54 100.0 
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Age in years 
Age 
 
 
Total No. of Patients      = 54 
Most common age group that present with goitre = 26-35 (42.6%) 
Least common age group that present with goitre = > 45 (7.4%) 
 46 
 
 
Sex Frequency Percent 
F 52 96.3 
M 2 3.7 
Total 54 100.0 
 
Female 
96% 
Male 
4% 
Sex 
 
 
Among 54 Patients  females are   = 52 (96.3%) 
Among 54 patients males are   = 2 (3.7%) 
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Pre operative Frequency Percent 
MNG 8 14.8 
SNT 46 85.2 
Total 54 100.0 
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Pre operative  
 
 
Among 54 patients 46 patients present as solitary nodular goitre  ( 85.2%) 
8 patients present as multinodular goitre (14.8%) 
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Surgery done Frequency Percent 
Hemi thyroidectomy 35 64.8 
SubTotal thyroidectomy 7 13.0 
Total thyroidectomy 12 22.3 
Total 54 100.0 
 
 
.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Hemi thyroidectomy SubTotal thyroidectomy Total thyroidectomy
P
e
rc
e
n
ta
g
e
  
Surgery done  
 
 
Among 54 patients Hemi thyroidectomy has done in 35 patients  64.8% 
Among 54 patients near total thyroidectomy has done in 7 patients 13% 
Among 54 patients total thyroidectomy has done in 12patients 22.3%  
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Age Group 
Final Diagnosis 
Total 
F.Ca P.Ca 
FOLLICULARCA+ 
PAPILLARYCA 
16-25 
 
MNG 0 0 0 2 
SNT 1 3 4 12 
26-35 
 
MNG 0 0 0 4 
SNT 1 3 4 19 
36-45 
 
MNG 0 1 1 1 
SNT 1 0 1 12 
46-55 
 
MNG 0 0 0 1 
SNT 0 1 1 3 
Note : F.Ca – Follicular carcinoma,  P.Ca – Papillary carcinoma 
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Comparison of Pre operative and final diagnosis in Age Group  
FOLLICULARCA PAPILLARYCA FOLLICULARCA+PAPILLARYCA
 
Among 12 patients 4 persons has malignancy in 16-25 age group (33%) 
Among 19 patients 4persons has malignancy in 26-35 age group (21%) 
Among 12 patients 1 person has malignancy in 36-45 age  group (8.3%) 
Among 3 patients 1 person has malignancy in 46-55 age group  (33%) 
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Sex 
Final Diagnosis   
F.Ca P.Ca 
FOLLICULARCA+ 
PAPILLARYCA 
Total 
Female  
  
MNG 0 1 1 6 
SNT 3 7 10 46 
Note : F.Ca – Follicular carcinoma,  P.Ca – Papillary carcinoma 
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Final diagnosis  
Comparison of Pre operative and final diagnosis in female  
MNG SNT
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Final Diagnosis 
Total 
F.Ca P.Ca 
FOLLICULARCA+ 
PAPILLARYCA 
Pre oper 
  
MNG 0 1 1 (12.5%) 8 
SNT 3 7 10(21.7%) 46 
Total 3 8 11 54 
Note : F.Ca – Follicular carcinoma,  P.Ca – Papillary carcinoma 
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Final diagnosis  
Comparison of pre operative and final diagnosis 
MNG SNT
 
 
Among the 46 patients of SNT 10 persons found to has malignancy 21.7% 
Among the 8 patients of MNG 1 person found to has malignancy 12.5% 
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Final Diagnosis Frequency Percent 
SNT 35 65 
MNG 8 15 
PAPILLARYCA 8 15 
FOLLICULARCA 3 5 
 
FOLLICULARCA 
5% 
MNG 
15% 
PAPILLARYCA 
15% 
SNT 
65% 
Final Diagnosis 
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Total No. of  Papillary Follicular Total 
Malignancy in both SNT & MNG 3 8 11 
 
Among the 54 patients papillary carcinoma found in 8 persons (14.8) 
Among the 54 patients follicular carcinoma found in 3 persons (5.5%) 
Total No of malignancies found in 54 patients are 11 (20.3%) 
 
Malignancy  Type Total No of patients Percentage 
Papillary Carcinoma 8 72.6 
Follicular Carcinoma 3 26.3 
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DISCUSSION 
INCIDENCE OF MALIGNANCY IN NODULAR GOITRE  
 Thyroid cancer is the ninth most common cancer in the female  
population.  These nodules are present in 4 – 7% of population.  Fewer than 5% 
of this nodules are malignant.  The most sensitive clinical predictor of 
malignancy in goiter is painless hard lump  (51%).  FNAC is fast accurate and 
inexpensive. 
MALIGNANCY IN SOLITARY NODULE 
 The prevalence of nodular goitre is usually high even in iodine sufficient 
areas, the incidence of cancer is considered  to be low.   FNAC is the most 
important advance in the management of thyroid nodules in the past decades.    
The treatment of this patients has been the focus of many controversies  over 
the years.    Even in improvement in treatment modalities some questions 
remain un resolved.  
 A single or multiple nodules present as common and important clinical 
entity.  The frequency of thyroid nodules  which are single on physical 
examination, increases throughout the life.   In the large Framingham database 
it has been estimated that the life time risk for developing thyroid nodule is 5 to 
10% of which 10-13%  are carcinomas.  Most benign and almost  all malignant 
thyroid nodules give  normal thyroid function test.   So TFT is not useful in 
distinguishing  a benign from malignant nodule.  
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 Ultra Sound can differentiate  between solid and cystic lesions but 
unfortunately there are no sonographic criteria at present that distinguish 
benign from the malignant nodules.  
 FNAC is the diagnostic procedure of choice  in SNT because it is safe 
and inexpensive leads to better prediction of patients has undergoing surgery 
than any other test.  The success of FNAC depends on experience of the person 
who performs the procedure and cytopathologist who interpreting the cells that 
are obtained. 
 The main indication of surgery is malignancy, suspicious cytologic 
features and the symptoms due to the nodule itself.  Incidence of malignancy in 
a solitary nodule is 20% 
Red flags for malignancy are male gender, extremes of age, rapid 
growth, symptoms of  invasion, past history of radiation to head and neck.  
INCIDENCE OF MALIGNANCY IN MULTI NODULAR GOITRE 
 MNG is the commonest indication for thyroidectomy  in endemic areas.  
Pre operative evaluation for thyroid malignancy by means of FNAC is difficult 
in MNG. Owing to the presence  of  multiple nodules, malignancy is frequently 
an unexpected postoperative finding.  Patients with MNG have been considered 
as lower risk of malignancy than those with solitary nodules.  However 
literature review has shown that the incidence of malignant tumors in patients 
with solitary nodule thus not differ much from MNG but the patient with tumor 
from underlying MNG are rising high percentage of the patients have 
lymphnode involvement and distant metastasis at initial presentation.   The 
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overall incidence of malignancy in worldwide was 4-11% it is comparable to 
our study which is 12.5 %. Papillary carcinoma is  most common among this.   
 An article published in Bahrain medical bulletin on December 2006 vol. 
28, quoted that the “study on frequency of malignancy in nodular goiter” of 
110 patients shows that 24%, which is comparable to our study.  
An article published in Journal of Endocrine practice on Aug 2009 pg.7-
13 quoted that a “study of incidence of malignancy in nodular goiter” is 16%,  
which is comparable to our study. 
An article published in surgery today of vol. 27 page 495, quoted that a 
study of malignancy in nodular goitre is around 5-15%. Which is comparable 
to our study.  
An article published at September 2005, pg 85-90, at Turkey the study 
of postoperative analysis of thyroidectomy specimens shows 18% of 
malignancy in SNT and 15% of malignancy in MNG among 518 patients, it is 
comparable to our study.  
A Study at Guntur Medical College between  2001 – 2004 with 98 
patients shows 12% of malignancy in SNT published on 13th Feb’ 2010. It 
various from 4 – 17 %, which is comparable to our study. 
An article published in 3rd April 2007 in Singapore by Hee nee pang 
shows 21% of malignancy in nodular goitre which is comparable  to our study.  
An article published on 2005 vol. 39, at turkey a ‘study of prospective 
analysis on course of thyroidectomy’ shows 18% of malignancy in SNT, and 
15% of malignancy in MNG, which is comparable to our study.    
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An article published at Hong kong Medical Journal on September 2001 
vol. 7 quoted that a study on outcomes of thyroid surgery by a surgeon T.L. 
chow shows 20% malignancy in SNT. which is comparable to our study. 
An article published in Asian Pacific Journal of cancer prevention 
Vol.10, 2009 a study on view of thyroid cancers in Malaysia shows 28 % of 
malignancy in nodular goiter of 11 year period with predominately papillary 
type which is comparable our study.  
An article published in Bahrain Medical bullet on Dec’ 2004 vol. 26, 
shows 30% of malignancy in nodular goitre in the study of 835 patients.  
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CONCLUSION 
 Average age group of patients present with nodular goitre in our 
institution  is 16-35, it is comparable to other studies. 
 Females are predominant sex group presented with nodular goitre.  
 Majority of the malignancies are presented as solitary nodule. 
 Maximum number of malignancies occurred in 16 to 35 age group. 
 Frequency of malignancy is greater in solitary nodular goitre than multi 
nodular goitre.  
 Frequency of  malignancy in nodular goitre is 20% it is comparable to 
other studies. 
 Papillary type of carcinoma is the predominant type of malignancy 
presented.  
 All postoperative thyroid specimens should be subjected to detailed 
histopathology to detect microscopic malignant foci.  
 Due to its high accuracy and cost effectiveness FNAC plays significant 
role in the diagnosis of thyroid malignancy and management.  
 Incidence of thyroid malignancy in nodular goitre it present in our 
hospital is significant.  FNAC and Ultra sound are important tools for 
the assessment of this goitres.    
 The risk of malignancy in MNG should not be under estimated as the 
incidence of malignancy in MNG is raising.   
 Dominant nodule in MNG should be considered as significant like 
solitary nodule. 
 Total thyroidectomy in MNG removes the disease process completely 
and avoids the substantial risk of re-operative surgery. 
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PROFORMA 
Name :  
Age : 
Sex : 
Onset of Symptoms : 
D.O.A. : 
D.O.D. : 
PRE OP DIAGNOSIS : 
POST OP DIAGNOSIS : 
DATE OF SURGERY : 
SURGERY DONE : 
DURATION OF HOSPITALITY : 
INVESTIGATION : 
 THYROID PROFILE : 
 FNAC : 
 ENT OPINION : 
 X-RAY SOFT TISSUE NECK : 
HISTOPATHOLOGICAL REPORT : 
 AT ADMISSION AT DISCHARGE 
HB %   
TC/DC   
BLOOD SUGAR   
UREA   
CREATININE   
SERUM ELECTROLYTES   
BLOOD GROUPING   
USG NECK   
 
